Conference Coverage

Adding foot screening to eye clinic catches diabetic neuropathy

Publish date: September 27, 2016

 

AT EASD 2016

Dr. Tesfaye reported relationships with NeuroMetrix, Impeto Medical, Eli Lilly, Pfizer, Worwag Pharma, and TRIGOcare International.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Both prepregnancy and gestational diabetes bode ill for babies
MDedge Endocrinology
Brain atrophy is already evident in patients with prediabetes
MDedge Endocrinology
Insulin-dependent pilots can fly safely with glucose monitoring protocol
MDedge Endocrinology
Dulaglutide plus insulin glargine drops HbA1c in poorly controlled type 2
MDedge Endocrinology
Liraglutide cut risk of microvascular renal complications by 22% in type 2 diabetes; no eye benefit
MDedge Endocrinology
When 1 + 1 = 3: Rational drug combinations in type 2 diabetes
MDedge Endocrinology
Exenatide/dapagliflozin combo may be better in stubborn diabetes
MDedge Endocrinology
Severe foot pathology predicts death in diabetes
MDedge Endocrinology
FDA approves first-line combo therapy for type 2 diabetes
MDedge Endocrinology
Cutting routine glucometer readings saves time and money
MDedge Endocrinology